Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial
- 78 Downloads
The efficacy and safety of mycophenolate mofetil (MMF) has been studied in patients with systemic sclerosis (SSc)-related interstitial lung disease (ILD) with moderate–severe impairment. There is no study on its use in patients with mildly impaired lung function. The objective of this study is to determine the efficacy and safety of MMF for treating mild SSc-ILD (forced vital capacity (FVC) ≥ 70% predicted). This was a double-blind, randomized, placebo-controlled pilot trial. The subjects with SSc-ILD with FVC ≥ 70% were randomized to receive either MMF (2 g/day) or placebo for 6 months. FVC, diffusing capacity of lungs for carbon monoxide (DLCO), modified Rodnan skin score (mRSS), Short Form-36 (SF36v2), Mahler’s Dyspnoea Index (MDI), and 6-min walk distance (6MWD) were recorded at baseline and at 6 months. Forty-one subjects were included in the study (MMF: 20, placebo: 21). FVC decreased by a median of 2.7% (range − 21 to 9) in MMF arm and increased by 1% (range − 6 to 10) in placebo arm (p = 0.131). SF36v2 scores improved in both the groups. Median change in MDI (3 vs 3), DLCO (1% vs 1.5%), and 6MWD (0 m vs 0 m) was similar between the study groups. MMF was effective in improving mRSS (− 5 vs − 1, p = 0.045) compared to placebo. Adverse events occurred with similar frequency in both the study groups. In this pilot study, MMF did not result in significant improvement in lung function in SSc-ILD with minimally impaired lung function, but was effective in reducing the skin tightness. Larger studies are needed to confirm these findings. This study was registered at ClinicalTrials.gov (NCT02896205).
KeywordsSystemic sclerosis Interstitial lung disease Mycophenolate mofetil Spirometry Quality of life Modified Rodnan skin score
We would like to thank Ipca Laboratories Limited, Mumbai, India for supplying the study drugs, MMF and placebo free of cost. This study was investigator-initiated and none of the personnel from the drug company was involved in the design, performance, or data analysis of the study or writing or reviewing of the manuscript.
All authors contributed to the design of the study, interpretation of the data, manuscript preparation and critical revisions of the manuscript. All authors approved the final version submitted for publication and agree to be accountable for all aspects of the study. Conception and design of the study: GN, SKS, VD, AS and SD. Data collection: GS, AM and SJ. Statistical analysis and data interpretation: GN, SKS, AM, VD and SD. Manuscript preparation: GN, AM, VD and SD. Manuscript revision: GN, SKS, VD, AS, SD and SJ.
No funding was received by any of the authors.
Compliance with ethical standards
Conflict of interest
GSRSNK Naidu, Shefali Khanna Sharma, Adarsh MB, Varun Dhir, Anindita Sinha, Sahajal Dhooria and Sanjay Jain declare that they have no conflict of interest. All the authors declare that they have no relationship with the organization promoting MMF.
A written informed consent was obtained from all the participants included in this study and no identifying information of any participant was included in this article.
The study was approved by the Institute of Ethics Committee (Ref. No. NK/2612/DM/10772). All the procedures performed in this study were in accordance to the guidelines set up by the Declaration of Helsinki in 1964 and later amended in 2000.
- 4.McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, Mayes MD (2007) Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 57:318–326. https://doi.org/ 10.1002/art.22532CrossRefGoogle Scholar
- 5.Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, Aggarwal AN, Behera D (2018) Spectrum of interstitial lung diseases at a tertiary center in a developing country: a study of 803 subjects. PLoS ONE 13:e0191938. https://doi.org/10.1371/journal.pone.0191938 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970. https://doi.org/10.1002/art.22204 CrossRefPubMedGoogle Scholar
- 8.Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double blind, parallel group trial. Lancet Respir Med 4:708–719. https://doi.org/10.1016/S2213-2600(16)30152-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N, Li KH, Dunne J, Wilcox PG, Ryerson CJ (2018) Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann Am Thorac Soc 15:1427–1433. https://doi.org/10.1513/AnnalsATS.201806-362OC CrossRefPubMedGoogle Scholar
- 14.van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755. https://doi.org/10.1136/annrheumdis-2013-204424 CrossRefPubMedGoogle Scholar
- 15.Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force (2005) Standardisation of spirometry. Eur Respir J 26:319–338. https://doi.org/10.1183/09031936.05.00034805 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pederson OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735. https://doi.org/10.1183/09031936.05.00034905 CrossRefPubMedGoogle Scholar
- 19.Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S (2016) Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 18:123. https://doi.org/10.1186/s13075-016-1015-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L et al (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76:1207–1218. https://doi.org/10.1136/annrheumdis-2016-210503 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Maruish ME (2011) User’s manual for the SF-36v2 Health Survey, 3rd edn. Quality Metric Incorporated, Lincoln, RIGoogle Scholar
- 31.Khanna D, Tseng CH, Furst DE, Clements PJ, Elashoff R, Roth M, Elashoff D, Tashkin DP (2009) Minimally important differences in the Mahler’s transition dyspnoea index in a large randomized controlled trial- results from the scleroderma lung study. Rheumatology (Oxford) 48:1537–1540. https://doi.org/10.1093/rheumatology/kep284 CrossRefGoogle Scholar
- 33.Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP (2019) Minimal clinically important differences for the modified Rodnan skin score: results from the scleroderma lung studies (SLS-I and SLS-II). Arthritis Res Ther 21:23. https://doi.org/10.1186/s13075-019-1809-y CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Udwadia ZF, Mullerpattan JB, Balakrishnan C, Richeldi L (2015) Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India 32:50–52. https://doi.org/10.4103/0970-2113.148451 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Khanna D, Albera C, Fischer A, Khalidi A, Raghu G, Chung L, Chen D, Schiopu E, Tagliaferri M, Seibold JR, Gorina A (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. J Rheumatol 43:1672–1679. https://doi.org/10.3899/jrheum.151322 CrossRefPubMedGoogle Scholar